Annals of Oncology路 @Annals_Oncology 路 X路路 3 days agoScore70
Body 路 original
馃摙 #ESMO26 concomitant paper - Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
馃敆https://tinyurl.com/3mx946h6
@brian_rini @tompowles1
28 views 路 0 likes 路 0 reposts 路 0 replies
Source: Annals of Oncology 路 x.com